Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts
Albany, New York, Feb 08, 2017
"Global
Regenerative Medicine Partnering 2010-2017: Deal trends, players,
financials and forecasts"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
The
Global Regenerative Medicine Partnering 2010-2017: Deal trends,
players, financials and forecasts report provides comprehensive
understanding and unprecedented access to the regenerative medicine
including cell therapy, organ regeneration, stem cells and tissue
regeneration partnering deals and agreements entered into by the
worlds leading healthcare companies.
Trends
in regenerative medicine
Deal
terms analysis
Partnering
agreement structure
Partnering
contract documents
Top
deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.
The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 950 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Regenerative Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Regenerative Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Regenerative Medicine dealmaking with a brief summary followed by a comprehensive listing of Regenerative Medicine deals announded by that company, as well as contract documents, where available.
Most active dealmakers
Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.
The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 950 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Regenerative Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Regenerative Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Regenerative Medicine dealmaking with a brief summary followed by a comprehensive listing of Regenerative Medicine deals announded by that company, as well as contract documents, where available.
….......
Other Details
Comments
Post a Comment